New Drugs

FDA Approves Nyvepria (pegfilgrastim-apgf), a Biosimilar to Neulasta

Written by David Miller

NEW YORK–(BUSINESS WIRE)– June 11, 2020 — Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Nyvepria (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 Nyvepria is…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]